CDC Reports National Rise in Parainfluenza
Parainfluenza virus activity is currently high across the US, while HMPV and rhinovirus/enterovirus levels are beginning to decline, according to the CDC.
Parainfluenza virus activity is currently high across the US, while HMPV and rhinovirus/enterovirus levels are beginning to decline, according to the CDC.
Research involving 2.5 million patients found no increase in serious adverse events when receiving both COVID-19 and influenza vaccinations during the same visit.
Researchers found that five core values—safety, knowledge, trust, humanity, and autonomy—shape how minority parents approach pediatric vaccination.
The FDA approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment for acute uncomplicated influenza and prophylaxis in patients 5 years of age and older.
Real-world data published in JAMA Network Open confirm the effectiveness of the RSVpreF vaccine in protecting newborns from respiratory syncytial virus.
The USFDA approved an expanded indication for Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to include children and adolescents aged 2 through 17 years, according to Merck.